Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Commentary: Science and stocks

Totalling up the stock price gainers for the third quarter, we were struck by the mix of high quality and not-so-high quality companies rewarded by investors. When, we wondered, will investors become more discriminating about the sector and, more importantly, when will stocks start sorting themselves out into tiers?

The answer to the first question is "probably never," as there will always be investors who buy on hype or shun the effort to acquire knowledge that would result in informed investments. It's also much easier for a stock to double in price from $2.50 to $5 than from $10 to $20.

Read the full 1005 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE